129 related articles for article (PubMed ID: 22196514)
1. Pyrrolo[1,2-b]pyridazines, pyrrolo[2,1-f]triazin-4(3H)-ones, and related compounds as novel corticotropin-releasing factor 1 (CRF₁) receptor antagonists.
Saito T; Obitsu T; Kohno H; Sugimoto I; Matsushita T; Nishiyama T; Hirota T; Takeda H; Matsumura N; Ueno S; Kishi A; Kagamiishi Y; Nakai H; Takaoka Y
Bioorg Med Chem; 2012 Jan; 20(2):1122-38. PubMed ID: 22196514
[TBL] [Abstract][Full Text] [Related]
2. 8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.
Gilligan PJ; He L; Clarke T; Tivitmahaisoon P; Lelas S; Li YW; Heman K; Fitzgerald L; Miller K; Zhang G; Marshall A; Krause C; McElroy J; Ward K; Shen H; Wong H; Grossman S; Nemeth G; Zaczek R; Arneric SP; Hartig P; Robertson DW; Trainor G
J Med Chem; 2009 May; 52(9):3073-83. PubMed ID: 19361210
[TBL] [Abstract][Full Text] [Related]
3. Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF₁) receptor antagonists.
Saito T; Obitsu T; Minamoto C; Sugiura T; Matsumura N; Ueno S; Kishi A; Katsumata S; Nakai H; Toda M
Bioorg Med Chem; 2011 Oct; 19(20):5955-66. PubMed ID: 21930387
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
Gilligan PJ; Clarke T; He L; Lelas S; Li YW; Heman K; Fitzgerald L; Miller K; Zhang G; Marshall A; Krause C; McElroy JF; Ward K; Zeller K; Wong H; Bai S; Saye J; Grossman S; Zaczek R; Arneric SP; Hartig P; Robertson D; Trainor G
J Med Chem; 2009 May; 52(9):3084-92. PubMed ID: 19361209
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist.
Chen YL; Mansbach RS; Winter SM; Brooks E; Collins J; Corman ML; Dunaiskis AR; Faraci WS; Gallaschun RJ; Schmidt A; Schulz DW
J Med Chem; 1997 May; 40(11):1749-54. PubMed ID: 9171885
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and structure-activity relationships of pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonists.
Dzierba CD; Sielecki TM; Arvanitis AG; Galka A; Johnson TL; Takvorian AG; Rafalski M; Kasireddy-Polam P; Vig S; Dasgupta B; Zhang G; Molski TF; Wong H; Zaczek RC; Lodge NJ; Combs AP; Gilligan PJ; Trainor GL; Bronson JJ; Macor JE
Bioorg Med Chem Lett; 2012 Aug; 22(15):4986-9. PubMed ID: 22749422
[TBL] [Abstract][Full Text] [Related]
7. 5-arylamino-1,2,4-triazin-6(1H)-one CRF1 receptor antagonists.
Schmitz WD; Brenner AB; Bronson JJ; Ditta JL; Griffin CR; Li YW; Lodge NJ; Molski TF; Olson RE; Zhuo X; Macor JE
Bioorg Med Chem Lett; 2010 Jun; 20(12):3579-83. PubMed ID: 20483614
[TBL] [Abstract][Full Text] [Related]
8. Cyclopenta[d]pyrimidines and dihydropyrrolo[2,3-d]pyrimidines as potent and selective corticotropin-releasing factor 1 receptor antagonists.
Arban R; Benedetti R; Bonanomi G; Capelli AM; Castiglioni E; Contini S; Degiorgis F; Di Felice P; Donati D; Fazzolari E; Gentile G; Marchionni C; Marchioro C; Messina F; Micheli F; Oliosi B; Pavone F; Pasquarello A; Perini B; Rinaldi M; Sabbatini FM; Vitulli G; Zarantonello P; Di Fabio R; St-Denis Y
ChemMedChem; 2007 Apr; 2(4):528-40. PubMed ID: 17335099
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and structure-activity relationships of novel pyrazolo[5,1-b]thiazole derivatives as potent and orally active corticotropin-releasing factor 1 receptor antagonists.
Takahashi Y; Hashizume M; Shin K; Terauchi T; Takeda K; Hibi S; Murata-Tai K; Fujisawa M; Shikata K; Taguchi R; Ino M; Shibata H; Yonaga M
J Med Chem; 2012 Oct; 55(19):8450-63. PubMed ID: 22971011
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonists.
Dzierba CD; Takvorian AG; Rafalski M; Kasireddy-Polam P; Wong H; Molski TF; Zhang G; Li YW; Lelas S; Peng Y; McElroy JF; Zaczek RC; Taub RA; Combs AP; Gilligan PJ; Trainor GL
J Med Chem; 2004 Nov; 47(23):5783-90. PubMed ID: 15509177
[TBL] [Abstract][Full Text] [Related]
11. The CRF(1) receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats.
McElroy JF; Ward KA; Zeller KL; Jones KW; Gilligan PJ; He L; Lelas S
Psychopharmacology (Berl); 2002 Dec; 165(1):86-92. PubMed ID: 12474122
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, structure-activity relationships, and anxiolytic activity of 7-aryl-6,7-dihydroimidazoimidazole corticotropin-releasing factor 1 receptor antagonists.
Han X; Michne JA; Pin SS; Burris KD; Balanda LA; Fung LK; Fiedler T; Browman KE; Taber MT; Zhang J; Dubowchik GM
Bioorg Med Chem Lett; 2005 Sep; 15(17):3870-3. PubMed ID: 15990298
[TBL] [Abstract][Full Text] [Related]
13. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
[TBL] [Abstract][Full Text] [Related]
14. Discovery of pyrrolo[2,3-d]pyrimidin-4-ones as corticotropin-releasing factor 1 receptor antagonists with a carbonyl-based hydrogen bonding acceptor.
Aso K; Kobayashi K; Mochizuki M; Kanzaki N; Sako Y; Yano T
Bioorg Med Chem Lett; 2011 Apr; 21(8):2365-71. PubMed ID: 21414781
[TBL] [Abstract][Full Text] [Related]
15. 4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
He L; Gilligan PJ; Zaczek R; Fitzgerald LW; McElroy J; Shen HS; Saye JA; Kalin NH; Shelton S; Christ D; Trainor G; Hartig P
J Med Chem; 2000 Feb; 43(3):449-56. PubMed ID: 10669572
[TBL] [Abstract][Full Text] [Related]
16. Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines.
Arvanitis AG; Gilligan PJ; Chorvat RJ; Cheeseman RS; Christos TE; Bakthavatchalam R; Beck JP; Cocuzza AJ; Hobbs FW; Wilde RG; Arnold C; Chidester D; Curry M; He L; Hollis A; Klaczkiewicz J; Krenitsky PJ; Rescinito JP; Scholfield E; Culp S; De Souza EB; Fitzgerald L; Grigoriadis D; Tam SW; Shen HL
J Med Chem; 1999 Mar; 42(5):805-18. PubMed ID: 10072679
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists.
Hartz RA; Ahuja VT; Arvanitis AG; Rafalski M; Yue EW; Denhart DJ; Schmitz WD; Ditta JL; Deskus JA; Brenner AB; Hobbs FW; Payne J; Lelas S; Li YW; Molski TF; Mattson GK; Peng Y; Wong H; Grace JE; Lentz KA; Qian-Cutrone J; Zhuo X; Shu YZ; Lodge NJ; Zaczek R; Combs AP; Olson RE; Bronson JJ; Mattson RJ; Macor JE
J Med Chem; 2009 Jul; 52(14):4173-91. PubMed ID: 19552437
[TBL] [Abstract][Full Text] [Related]
18. Potential CRF1R PET imaging agents: N-fluoroalkyl-8-(6-methoxy-2-methylpyridin-3-yl)-2,7-dimethyl-N-alkylpyrazolo[1,5-a][1,3,5]triazin-4-amines.
Zuev D; Mattson RJ; Huang H; Mattson GK; Zueva L; Nielsen JM; Kozlowski ES; Huang XS; Wu D; Gao Q; Lodge NJ; Bronson JJ; Macor JE
Bioorg Med Chem Lett; 2011 Apr; 21(8):2484-8. PubMed ID: 21411322
[TBL] [Abstract][Full Text] [Related]
19. 6,7-Dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives as novel corticotropin-releasing factor 1 receptor antagonists.
Saito T; Obitsu T; Kondo T; Matsui T; Nagao Y; Kusumi K; Matsumura N; Ueno S; Kishi A; Katsumata S; Kagamiishi Y; Nakai H; Toda M
Bioorg Med Chem; 2011 Sep; 19(18):5432-45. PubMed ID: 21865047
[TBL] [Abstract][Full Text] [Related]
20. Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats.
Lelas S; Wong H; Li YW; Heman KL; Ward KA; Zeller KL; Sieracki KK; Polino JL; Godonis HE; Ren SX; Yan XX; Arneric SP; Robertson DW; Hartig PR; Grossman S; Trainor GL; Taub RA; Zaczek R; Gilligan PJ; McElroy JF
J Pharmacol Exp Ther; 2004 Apr; 309(1):293-302. PubMed ID: 14742750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
